Last reviewed · How we verify
echinacea/sage
echinacea/sage is a Small molecule drug developed by A. Vogel AG. It is currently in Phase 3 development for Symptomatic relief of sore throat associated with upper respiratory tract infections.
Echinacea/sage combination acts to reduce symptoms of sore throat and upper respiratory tract infections through its anti-inflammatory and antimicrobial properties.
Echinacea/sage combination acts to reduce symptoms of sore throat and upper respiratory tract infections through its anti-inflammatory and antimicrobial properties. Used for Symptomatic relief of sore throat associated with upper respiratory tract infections.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | echinacea/sage |
|---|---|
| Sponsor | A. Vogel AG |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Echinacea is known for its immune-stimulating effects and ability to inhibit viral replication, while sage has potent anti-inflammatory and astringent properties that help soothe mucous membranes in the throat.
Approved indications
- Symptomatic relief of sore throat associated with upper respiratory tract infections
Common side effects
- Gastrointestinal discomfort
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- echinacea/sage CI brief — competitive landscape report
- echinacea/sage updates RSS · CI watch RSS
- A. Vogel AG portfolio CI
Frequently asked questions about echinacea/sage
What is echinacea/sage?
How does echinacea/sage work?
What is echinacea/sage used for?
Who makes echinacea/sage?
What development phase is echinacea/sage in?
What are the side effects of echinacea/sage?
Related
- Manufacturer: A. Vogel AG — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Symptomatic relief of sore throat associated with upper respiratory tract infections
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing